You are here
Home > Business > Global Autoimmune Disease Diagnostics Market 2018 Scope, Share, Growth, Overview and Forecast to 2023

Global Autoimmune Disease Diagnostics Market 2018 Scope, Share, Growth, Overview and Forecast to 2023

Global Autoimmune Disease Diagnostics Market 2018–2023:

The global autoimmune disease diagnostics market is expected to register a CAGR of 7.5% during the forecast period of 2018–2023.The key factors propelling the market include the growing public awareness of autoimmune disease, improving laboratory automation, partnerships with physicians and clinical laboratories, technological advancements, expansion in coverage allowed by the Patient Protection and Affordable Care Act.

Major Players: F. HOFFMANN-LA ROCHE, EUROIMMUN AG, INOVA DIAGNOSTICS, INC., SIEMENS HEALTHINEERS, INC., BIOMÉRIEUX, TRINITY BIOTECH, THERMO FISHER SCIENTIFIC, MYRIAD GENETICS, ABBOTT LABORATORIES, and BIO-RAD LABORATORIES, among others.

Get Sample Copy of Global Autoimmune Disease Diagnostics Market @ http://orbisresearch.com/contacts/request-sample/2131406

Companies Mentioned:
F. Hoffmann-la Roche, Euroimmun AG, Inova Diagnostics, Inc., Siemens Healthineers, Inc., Biomérieux, Trinity Biotech, Thermo Fisher Scientific, Myriad Genetics, Abbott Laboratories, Bio-rad Laboratories

Growing Public Awareness of Autoimmune Disease
The rising awareness of autoimmune diseases through programs of research, education, support, and advocacy is a key factor boosting the usage rates. It is imperative that the public is more aware of their own risk factors for developing autoimmune diseases so that, as symptoms occur, they can seek diagnosis and begin a treatment regimen. The United States has the highest incidence of autoimmune diseases with about 50 million patients. The American Autoimmune Related Diseases Association (AARDA) is dedicated to eradicate autoimmune diseases. The AARDA aims to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. Similarly, there are other organizations who are striving to improve the R&D funding, patient awareness, and provide other socio-economic benefits to the patients. The increase in awareness levels coupled with improving healthcare infrastructure and reimbursement coverage is expected to drive the market expansion over the forecast period. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, technological advancements, and expansion in coverage allowed by the Patient Protection and Affordable Care Act are driving the autoimmune disease diagnostics market.

Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results
Diagnosis of autoimmune diseases is a time-consuming process. It involves procedures such as serum testing for diseases like rheumatoid arthritis, Addison’s disease, Hashimoto’s disease, and others. Testing protocols allow autoimmune disorders to be diagnosed in a highly efficient and cost-effective manner. However, the turnaround time for the test results is slow, owing to lesser automation techniques. It takes days to deliver all test results to the patients with the proper explanation of false positive results. For example, autoimmune lymph proliferative syndrome is an autoimmune disease with a turnaround time of up to 12 weeks. A single gene sequencing takes four weeks. Therefore, this slow turnaround time is hindering the global autoimmune disease diagnostics market. The other factor, such as high frequency of false positive result is also hindering the market.

United States to Lead the Market in North America
In 2017, the United States autoimmune disease diagnostics market held the largest market share in North America due to the increasing healthcare expenditure and increasing prevalence of autoimmune diseases in the region. In the United States, 16% of the population suffers from autoimmune diseases, 78% of whom are women.

Enquire Before Buying Global Autoimmune Disease Diagnostics Market Report @ http://orbisresearch.com/contacts/enquiry-before-buying/2131406

Key Developments in the Market
October 2017: The US Food and Drug Administration cleared Roche’s Cobas Cdiff Nucleic acid test.
August 2017: BioMérieux, received SERVICE 800 award in an annual conference held in Minneapolis.
August 2017: Thermo Fisher Scientific acquired Patheon.

Reasons to Purchase the Report
Follow the current and future autoimmune disease diagnostics market in the developed and emerging markets.
Examining the various perspectives of the market with the help of Porter’s Five Forces Analysis.
Identify the segment that is expected to dominate the market.
Identify the regions that are expected to witness the fastest growth during the forecast period.
Identify the latest developments, market shares, and strategies employed by the major market players.
3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table Of Content:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

Continued…

Place Purchase Order for Global Autoimmune Disease Diagnostics Market Report @ http://orbisresearch.com/contact/purchase/2131406

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:
Hector Costello
Senior Manager — Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas — 75204, U.S.A.
Phone No.: +1 (214) 884–6817; +9164101019
Email: sales@orbisresearch.com

Leave a Reply

Top